Hubei Jumpcan Pharmaceutical Valuation
Is 600566 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 600566 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 600566 (CN¥30.01) is trading below our estimate of fair value (CN¥55.28)
Significantly Below Fair Value: 600566 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 600566?
Key metric: As 600566 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 600566's PE Ratio? | |
|---|---|
| PE Ratio | 9.9x |
| Earnings | CN¥2.78b |
| Market Cap | CN¥27.41b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.9x |
| Enterprise Value/EBITDA | 5.6x |
| PEG Ratio | 0.9x |
Price to Earnings Ratio vs Peers
How does 600566's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 54.7x | ||
002821 Asymchem Laboratories (Tianjin) | 41x | 29.9% | CN¥29.4b |
002262 Jiangsu Nhwa Pharmaceutical | 23.2x | 17.8% | CN¥26.2b |
600521 Zhejiang Huahai Pharmaceutical | 22.8x | 22.0% | CN¥25.4b |
600518 Kangmei Pharmaceutical | 131.8x | n/a | CN¥32.7b |
600566 Hubei Jumpcan Pharmaceutical | 9.9x | 10.7% | CN¥27.4b |
Price-To-Earnings vs Peers: 600566 is good value based on its Price-To-Earnings Ratio (9.9x) compared to the peer average (54.7x).
Price to Earnings Ratio vs Industry
How does 600566's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 600566 is good value based on its Price-To-Earnings Ratio (9.9x) compared to the CN Pharmaceuticals industry average (29.9x).
Price to Earnings Ratio vs Fair Ratio
What is 600566's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 9.9x |
| Fair PE Ratio | 25.3x |
Price-To-Earnings vs Fair Ratio: 600566 is good value based on its Price-To-Earnings Ratio (9.9x) compared to the estimated Fair Price-To-Earnings Ratio (25.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sichuan Kelun Pharmaceutical
CN¥47.5b
Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.
2422
CN¥31.84
7D
-3.9%
1Y
14.4%
Dong-E-E-JiaoLtd
CN¥37.4b
Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.
423
CN¥58.44
7D
-2.0%
1Y
18.4%
China Resources Double-Crane PharmaceuticalLtd
CN¥22.3b
China Resources Double-Crane Pharmaceutical Co.,Ltd.
600062
CN¥21.72
7D
-1.2%
1Y
18.8%